201 related articles for article (PubMed ID: 35987555)
1. Treatment-Refractory Dravet Syndrome: Considerations for Novel Medications.
Lopez JC; Pare JR; Blackmer AB; Orth LE
J Pediatr Health Care; 2022; 36(5):479-488. PubMed ID: 35987555
[TBL] [Abstract][Full Text] [Related]
2. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison.
Devi N; Madaan P; Asrar MM; Sahu JK; Bansal D
Seizure; 2021 Oct; 91():316-324. PubMed ID: 34274891
[TBL] [Abstract][Full Text] [Related]
3. A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.
Strzelczyk A; Schubert-Bast S
CNS Drugs; 2022 Mar; 36(3):217-237. PubMed ID: 35156171
[TBL] [Abstract][Full Text] [Related]
4. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
[TBL] [Abstract][Full Text] [Related]
5. Changing Landscape of Dravet Syndrome Management: An Overview.
Samanta D
Neuropediatrics; 2020 Apr; 51(2):135-145. PubMed ID: 32079034
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Lattanzi S; Trinka E; Russo E; Del Giovane C; Matricardi S; Meletti S; Striano P; Damavandi PT; Silvestrini M; Brigo F
Drugs; 2023 Oct; 83(15):1409-1424. PubMed ID: 37695433
[TBL] [Abstract][Full Text] [Related]
7. A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome.
Schoonjans AS; Ceulemans B
Expert Rev Neurother; 2022 May; 22(5):351-364. PubMed ID: 33455486
[TBL] [Abstract][Full Text] [Related]
8. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
Nabbout R; Mistry A; Zuberi S; Villeneuve N; Gil-Nagel A; Sanchez-Carpintero R; Stephani U; Laux L; Wirrell E; Knupp K; Chiron C; Farfel G; Galer BS; Morrison G; Lock M; Agarwal A; Auvin S;
JAMA Neurol; 2020 Mar; 77(3):300-308. PubMed ID: 31790543
[TBL] [Abstract][Full Text] [Related]
9. Fenfluramine (Fintepla) for Dravet syndrome.
Med Lett Drugs Ther; 2021 Aug; 63(1630):126-128. PubMed ID: 34550111
[No Abstract] [Full Text] [Related]
10. Stiripentol for the treatment of seizures in Dravet syndrome.
Eschbach K; Knupp KG
Expert Rev Clin Pharmacol; 2019 May; 12(5):379-388. PubMed ID: 31017478
[TBL] [Abstract][Full Text] [Related]
11. Dravet syndrome: Treatment options and management of prolonged seizures.
Cross JH; Caraballo RH; Nabbout R; Vigevano F; Guerrini R; Lagae L
Epilepsia; 2019 Dec; 60 Suppl 3():S39-S48. PubMed ID: 31904119
[TBL] [Abstract][Full Text] [Related]
12. Stiripentol for the treatment of seizures associated with Dravet syndrome.
Chiron C
Expert Rev Neurother; 2019 Apr; 19(4):301-310. PubMed ID: 30900478
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic advances in Dravet syndrome: a targeted literature review.
Strzelczyk A; Schubert-Bast S
Expert Rev Neurother; 2020 Oct; 20(10):1065-1079. PubMed ID: 32799683
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
[TBL] [Abstract][Full Text] [Related]
15. Dravet Syndrome: A Review of Current Management.
Wheless JW; Fulton SP; Mudigoudar BD
Pediatr Neurol; 2020 Jun; 107():28-40. PubMed ID: 32165031
[TBL] [Abstract][Full Text] [Related]
16. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.
Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B
Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834
[TBL] [Abstract][Full Text] [Related]
17. Pharmacotherapy for Dravet Syndrome.
Wallace A; Wirrell E; Kenney-Jung DL
Paediatr Drugs; 2016 Jun; 18(3):197-208. PubMed ID: 26966048
[TBL] [Abstract][Full Text] [Related]
18. Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome.
Polster T
Epilepsy Behav; 2019 Feb; 91():99-102. PubMed ID: 30269941
[TBL] [Abstract][Full Text] [Related]
19. Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome.
Lattanzi S; Zaccara G; Russo E; La Neve A; Lodi MAM; Striano P
Expert Rev Neurother; 2021 Jan; 21(1):99-110. PubMed ID: 33026899
[TBL] [Abstract][Full Text] [Related]
20. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis.
Sullivan J; Specchio N; Devinsky O; Auvin S; Perry MS; Strzelczyk A; Gil-Nagel A; Dai D; Galer BS; Gammaitoni AR
Epilepsia; 2022 Jan; 63(1):130-138. PubMed ID: 34676542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
